Adjuvant radiotherapy after prostatectomy for prostate cancer in Japan: a multi-institutional survey study of the JROSG

In Japan, the use of adjuvant radiotherapy after prostatectomy for prostate cancer has not increased compared with the use of salvage radiotherapy. We retrospectively evaluated the outcome of adjuvant radiotherapy together with prognostic factors of outcome in Japan. Between 2005 and 2007, a total o...

Full description

Saved in:
Bibliographic Details
Published in:Journal of radiation research 2014-05, Vol.55 (3), p.533-540
Main Authors: Aoki, Manabu, Mizowaki, Takashi, Akimoto, Tetsuo, Nakamura, Katsumasa, Ejima, Yasuo, Jingu, Keiichi, Tamai, Yoshifumi, Nakajima, Nobuaki, Takemoto, Shinya, Kokubo, Masaki, Katoh, Hiroyuki
Format: Article
Language:English
Subjects:
Adjuvants
Aged
Cancer
Cancer research
Disease-Free Survival
Health Care Surveys
Humans
Incidence
Japan - epidemiology
Male
Middle Aged
Neoplasm Recurrence, Local - mortality
Neoplasm Recurrence, Local - prevention & control
Oncology
Patients
Prognosis
Prostate
Prostate cancer
Prostatectomy - mortality
Prostatic Neoplasms - mortality
Prostatic Neoplasms - therapy
Radiotherapy
Radiotherapy, Adjuvant - mortality
Radiotherapy, Conformal - mortality
Retrospective Studies
Risk Factors
Surgery
Surveys
Survival
Survival Rate
Treatment Outcome
Vesicles
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In Japan, the use of adjuvant radiotherapy after prostatectomy for prostate cancer has not increased compared with the use of salvage radiotherapy. We retrospectively evaluated the outcome of adjuvant radiotherapy together with prognostic factors of outcome in Japan. Between 2005 and 2007, a total of 87 patients were referred for adjuvant radiotherapy in 23 institutions [median age: 64 years (54–77 years), median initial prostate-specific antigen: 11.0 ng/ml (2.9–284 ng/ml), Gleason score (GS): 6, 7, 8, 9, 10 = 13.8, 35.6, 23.0, 27.6, 0%, respectively]. Rates of positive marginal status, seminal vesicle invasion (SVI) and extra-prostatic extension (EPE) were 74%, 26% and 64%, respectively. Median post-operative PSA nadir: 0.167 ng/ml (0–2.51 ng/ml). Median time from surgery to radiotherapy was 3 months (1–6 months). A total dose of ≥60 Gy and 0.2 (P = 0.02), and tended to be more favorable after radiotherapy ≤3 months from surgery than >3 months from surgery (P = 0.069). Multivariate analysis identified SVI and post-operative PSA nadir as independent prognostic factors for bRFS (P = 0.001 and 0.018, respectively).
ISSN:0449-3060
1349-9157
DOI:10.1093/jrr/rrt137